Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study
Open Access
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 215, 408-415
Abstract
No abstract availableKeywords
Funding Information
- Dainippon Sumitomo Pharma
This publication has 24 references indexed in Scilit:
- Selective Overexpression of Dopamine D3 Receptors in the Striatum Disrupts Motivation but not CognitionBiological Psychiatry, 2014
- Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidoneNeuropsychiatric Disease and Treatment, 2014
- Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsPLOS ONE, 2014
- Risk factors for relapse following treatment for first episode psychosis: A systematic review and meta-analysis of longitudinal studiesSchizophrenia Research, 2012
- The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and AdultsAmerican Journal of Psychiatry, 2011
- Effect of dose timing in relation to food intake on systemic exposure to blonanserinEuropean Journal of Clinical Pharmacology, 2010
- Disengagement From Mental Health Treatment Among Individuals With Schizophrenia and Strategies for Facilitating Connections to Care: A Review of the LiteratureSchizophrenia Bulletin, 2009
- Depot and oral antipsychotics: patient preferences and attitudes are not the same thingJournal of Psychopharmacology, 2008
- Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With SchizophreniaPsychiatric Services, 2004
- A new five factor model of schizophreniaPsychiatric Quarterly, 1994